Platinum-Free Combination Chemotherapy in Patients with Advanced or Metastatic Transitional Cell Carcinoma: A Phase I/II Trial of Gemcitabine, Paclitaxel, and Methotrexate

Cancer

Volumn 100, Issue 1, 2004, Pages 82-88

  Lara Jr , Primo N ^a,b,d   Meyers, Frederick J ^a   Law, Lisa Y ^a   Dawson, Nancy A ^c   Houston, Joan ^a   Lauder, Ignacio ^b   Edelman, Martin J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b (VA) N California Hlth Care Syst   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gemcitabine; Methotrexate; Paclitaxel; Transitional cell carcinoma (TCC)

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLADDER CARCINOMA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMATURIA; HUMAN; HYPOCALCEMIA; INFECTION; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTIC SHOCK; SOMNOLENCE; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHOTREXATE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; UROLOGIC NEOPLASMS;

EID: 0346217048     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11866     Document Type: Article

References (28)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Harker WG, Meyers FJ, Freiha FS et al. Cisplain, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract-A Northern California Oncology Group study. J Clin Oncol. 1985;3:1463-1468.
3. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988;139:461-466.
4. Roth BJ, Bajorin D: Advanced bladder cancer: the need to identify new agents in the post-MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol. 1989;142:289-292.
5. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564-2569.
6. Small EJ, Fippin LJ, Ernest ML, et al. A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer. 1996;78:1775-1780.
7. Fuchs DA, Johnson RK. Cytologic evidence that Taxol, an antineoplastic agent from Taxus Brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep. 1978;62:1219-1222.
8. Roth B, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the ECOG. J Clin Oncol. 1994;12:2264-2270.
9. Murphy BA, Johnson DR, Smith J, et al. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer [abstract 617]. Proc Am Soc Clin Oncol. 1996;15:245a.
10. Dreicer R, Roth B, Lipsitz S, et al. E2895 cisplatin and paclitaxel in advanced carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group (ECOG) [abstract 1266]. Proc Am Soc Clin Oncol. 1999;17:320a.
11. Burch PA, Richardson RL, Cha SS, et al. Phase II trial combination paclitaxel and cisplatin in advanced urothelial carcinoma [abstract 1266]. Proc Am Soc Clin Oncol. 1999;18:329a.
12. Pollera CF, Ceribelli A, Crecco M, et al. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol. 1994;5:182-184.
13. Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum: Italian Cooperative Group on Bladder Cancer. Eur J Cancer. 1998;34:1208-1212.
14. Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patient with metastatic urothelial cancer. J Clin Oncol. 1997;15:3394-3398.
15. Moore MJ, Tannock I, Ernst S, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997;15:3441-3445.
16. von der Maase H, Andersoen L, Crino L, et al. A phase II study of gemcitabine and cisplatin in patients with transitional cell carcinoma (TCC) of the urothelium [abstract 1155]. Proc Am Soc Clin Oncol. 1997;16:324a.
17. Kaufman D, Stadler W, Carducci M, et al. Gemcitabine (GEM) plus cisplatin (CDDP) in metastatic transitional carcinoma (TCC): final results of a phase II study [abstract 1235]. Proc Am Soc Clin Oncol. 1998;17:320a.
18. Moore MJ, Winquist E, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17:2876-2880.
19. von der Masse, Hansen SW, Roberts IT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized multinational, multicenter phase III study. J Clin Oncol. 2000;18:3068-3077.
20. Raghavan, D. Progress in the chemotherapy of metastatic cancer of the urinary tract. Cancer. 2003;97(Suppl 8)2050-2055.
21. Yagoda A. Overview of systemic treatment of bladder cancer and results with M-VAC therapy. Prog Clin Biol Res. 1990;350:87-99.
22. Edelman MJ, Meyers FJ, Miller TR, et al. Phase I/II study of paclitaxel, carboplatin and methotrexate in advanced transitional cell carcinoma: A well-tolerated regimen with activity independent of p52 mutation. Urology. 2000;55:521-525.
23. Lim N, Lara PN, Jr., Lau DHM, et al Phase I trial of gemcitabine and paclitaxel in advanced solid tumors. Cancer Invest. 2003;21:7-13.
24. Sternberg CN, Calabro F, Pizzocaro G, et al. Chemotherapy with an every 2 week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin based therapy. Cancer. 2001;92:2993-2998.
25. Meluch AA, Greco FA, Burris HA, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2001;19:3018-3024.
26. Natale RB, Yagoda A, Watson RC, et al. Methotrexate: an active drug in bladder cancer. Cancer. 1981;47:1246-1250.
27. Small EJ, Lew D, Redman BG, et al. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol. 2000;18:2537-2544.
28. Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol. 1998;9:13-21.